Synthetic heparin derivatives as new anticoagulant drugs.
The journey towards a detailed mechanistic understanding of the anticoagulant action of heparin has resulted in synthetic mimetics with improved pharmacodynamic profiles. Inspired by the ternary complex formation of heparin with antithrombin III and thrombin, the active pentasaccharide fondaparinux has been succeeded by several clinical candidates, such as SR123781, that have tailor-made factor Xa and thrombin inhibitory activities combined with less aspecific binding (e.g. binding to platelet factor 4 involved in thrombocytopenia). Novel compounds with both antithrombin III-mediated inhibition of factor Xa and direct thrombin inhibition are emerging. Org42675 is one such compound, balancing dual inhibition of factor Xa and thrombin in one anticoagulant drug, with excellent pharmacokinetic properties and strong inhibitory activity toward clot-bound thrombin.
de Kort
Martin
M
NV Organon, Molenstraat 110, 5340 BH, Oss, The Netherlands. m.dekort@organon.com
Buijsman
Rogier C
RC
van Boeckel
Constant A A
CA
D000925:Anticoagulants / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000493:pharmacokinetics; D065427:Factor Xa Inhibitors; D006493:Heparin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D013329:Structure-Activity Relationship; D013921:Thrombocytopenia / Q000139:chemically induced
D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D006493:Heparin